Selection of control subjects in genetic studies of diabetes mellitus
Dear Sir, Pozzilli and colleagues [1] draw our attention once again to the problems of assembling groups for the study of genetic associations in Type I (insulin-dependent) diabetes. The importance of ethnic matching is irrefutable but we would suggest that difficulties are not limited to the control group -significant problems may arise in the collection of affected subjects.
There is considerable evidence that both Type 1 and Type 2 (non-insulin-dependent) diabetes are heterogenous categories [2, 3] . Similarly, in Type 1 diabetes, insulinitis may be the common reaction to a number of different environmental agents (e. g. different viruses) and even auto-immunity itself may be genetically heterogenous. Thus, it is reductionist to view all patients as belonging to a homogenous group of either Type i or Type 2 disease. We, therefore, suggest that before the question of suitable control subjects is addressed, attention be paid to collecting homogenous affected populations. In Type 1 diabetes this may be possible by concentrating on sub-groups with certain auto-antibody specificities or distinctive clinical time course. In Type 2 diabetes, we have previously shown that associations with RFLP (restriction fragment length polymorphism) markers linked to the GLUT2 gene were only seen in those subjects with affected first degree relatives [4] . It may be that this sub-group was particularly homogenous for GLUT2 defects. More recently, Groop et al. [5] reported that an association between Type 2 diabetes and a glycogen synthetase polymorphism was also more pronounced in subjects with a positive family history for the disease.
The important point to remember is that these studies are case~control studies. Ideally each case should be individually matched to several controls. The current practice of collecting a heterogenous group of affected subjects and comparing them with a group of non-affected individuals from the same ethnic group is far from satisfactory. Individual matching of cases to controls will require more careful analysis of the clinical, metabolic and immune profiles of subjects. In Cardiff a large cohort of patients with newlypresenting and untreated Type 2 diabetes have been the subject of intensive metabolic study for many years. We hope that this approach will allow the recruitment of a relatively homogenous population of diabetic patients to which unaffected control subjects can be individually matched with respect not only to ethnic origin but also to parameters of insulin secretion and resistance.
Yours sincerely,
